Avsnitt
-
The syphilis epidemic in the U.S. is a growing public health crisis, with rates increasing by 76% from 2018 to 2022. Syphilis is preventable and curable, but early detection is key—especially for pregnant women, where timely testing can prevent congenital syphilis.
Don’t miss this episode on the solutions to this growing epidemic.
About Our Speaker:
Dr. Lily Li is the Senior Director of Medical, Scientific & Clinical Affairs at QuidelOrtho. With a medical degree from Peking University and a PhD in Immunology from the University of Alberta, Dr. Li has guided the development of multiple infectious disease diagnostic tests at QuidelOrtho.
-
Did you know that women are 10 times more likely than men to develop a thyroid condition, yet often remain undiagnosed due to medical bias and lack of awareness? We often see women present themselves to an emergency department with health concerns that are brushed off as “stress” or “weight-related” versus conducting diagnostic testing to identify the root cause.
How can we address that?
Don’t miss this episode on how healthcare providers can address these types of biases including timeliness of diagnosis, screening practices, and interpretation of lab results to enhance the quality of care for women with thyroid conditions.
About our speaker
Jeff Houtz, Senior Global Product Manager
Jeff Houtz is the Senior Global Product Manager for QuidelOrtho covering thyroid and reproductive endocrine products. Jeff has 35 years of experience in research and development, product development, and medical education in a variety of disease states including reproductive and thyroid disorders. Providing accurate and meaningful diagnoses in furtherance of improved healthcare has always been a driver and motivator. Jeff has been instrumental in creating numerous CME and P.A.C.E.-accredited content for physicians, nurses, and laboratorians in the U.S. and Europe.
In addition to assay development Jeff is passionate about patient advocacy which is why he has worked closely with the Graves’ Disease and Thyroid Foundation and Thyroid Federation International. Jeff has also collaborated with LifeTime TV in support of programs on The Balancing Act and Access Health surrounding thyroid disease.
Jeff is also a family man married for 30 years with 2 wonderful kids.
-
Saknas det avsnitt?
-
The World Health Organization estimates 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection, the main cause of oral herpes, and 491 million people aged 15–49 (13%) worldwide have a herpes simplex virus type 2 (HSV-2) infection, the main cause of genital herpes. Although treatable, most HSV infections are often asymptomatic or unrecognized. Moreover, management of HSV infections is complicated by overlapping clinical presentation of unrelated herpesvirus infections, such as varicella-zoster virus (VZV), requiring differential diagnosis. Innovations in molecular diagnostics continue to play a critical role in the diagnosis and management of these diseases.
About Our Speaker:
Lori Henderson earned a bachelor’s degree in biology from Bucknell University. She began her career in the laboratory working on drug discovery and then transitioned into commercial roles within the biopharma and diagnostics sectors of the life science industry. Lori has direct experience in multiple disease and therapeutic areas and currently focuses on sexually transmitted diseases and women’s health. Within the molecular business unit at QuidelOrtho, Lori is responsible for identifying and helping drive the development of products to meet clinical and patient needs.
-
Sickle cell disease (SCD) patients are at risk of developing multiple complications from transfusions, including alloimmunization to red blood cell antigens, delayed hemolytic transfusion reactions and hyperhemolysis syndrome (HHS). While HHS is a rare complication of repeat blood transfusions in patients with SCD, clinicians and the laboratory have important roles in its detection and management.In this podcast, Wally R. Smith, MD, the inaugural Florence Neal Cooper Smith Professor of Sickle Cell Disease at Virginia Commonwealth University shares insights to screening for and managing HHS.
About Our Speaker:
Wally R. Smith, MD, is an experienced implementation scientist and expert in clinical and health services research in sickle cell disease (SCD). He serves as Vice Chair for Research of the Division of General Internal Medicine at Virginia Commonwealth University (VCU) and was Scientific Director of the Center on Health Disparities at VCU. Dr. Smith has authored over 100 publications and served as an investigator on over 50 grants and contracts. He has been principal investigator on 26 federal or foundation-funded grants and contracts including: Pain in Sickle Cell Epidemiology Study (PiSCES), the largest and most detailed adult cohort that changed our understanding of SCD pain in adults and, since 2012, Start Healing in Patients with Hydroxyurea, the first-ever randomized controlled trial of implementation science in SCD.
-
Six Sigma is a popular way to measure quality. Sigma metrics have been adapted for the clinical laboratory by incorporating observed accuracy, precision and total error allowed (TEa). In vitro diagnostic (IVD) manufacturers have used Six Sigma to assess the quality of their assays using a small number of well-controlled systems to generate the data. QuidelOrtho has developed a novel approach to assess laboratory Sigma metrics for a broad range of assays using data from over 1,300 Vitros® instruments used in clinical labs.
In this podcast, Johanna Miller, data scientist at QuidelOrtho, discusses the value of using real-world data to perform Sigma metric studies and how a lab can use this information.
About Our Speaker:
Johanna Miller holds a bachelor's degree in biomedical engineering from the University of Rochester and a master's in product development and data science from the Rochester Institute of Technology. She spent 10 years developing expertise on Vitros systems and the data it generates, while working in product development. Currently, she focuses on developing new and interesting methods to use data at QuidelOrtho - specifically to bring insights directly to labs using Six Sigma quality scores.
-
Reference intervals (RIs) are a fundamental decision support tool used by clinicians and lab professionals to interpret laboratory reports and assess an individual’s health status. The establishment of reference intervals, however, can be challenging due to many physiological factors that influence their values and heterogeneities that inherently exist in populations.
In this podcast, Dr. Lindy Crimmins will provide a comprehensive explanation of the influencing factors and evolving methodology of RIs from how they are established to how they are advancing.
About Our Speaker:
Dr. Lindy Crimmins is a Manager of Medical Affairs at QuidelOrtho. She holds a Bachelor’s degree in Chemistry from the University of Wisconsin-Madison and a Medical Degree from the University of Illinois. Her clinical experience spanned from Emergency Medicine to critical care to primary care. Her time in the industry focused on clinical chemistry and point-of-care technical support prior to Medical and Scientific Affairs. Currently, she is responsible for providing medical support for QuidelOrtho’s acute care menu throughout the product lifecycle.
-
Each year 4.5 million lives are saved by blood transfusions thanks to blood donations. More than 118 million units of blood are donated worldwide every year but less than 10% of people who can donate blood will give. These repeat blood donors enjoy benefits of their own while providing their lifesaving gift. Donating blood burns 650 calories, reduces stress, provides an emotional lift and has physiological benefits.
In this podcast, Dr. Mark A. Levine shares the critical importance of blood donation and how repeat donors enjoy both emotional and physical health benefits.
About Our Speaker:
Dr. Levine is an award-winning physician and lecturer with interests in health professional education, the history of medicine and community empowerment. For 14 years, he served as Chief Medical Officer at the Centers for Medicare and Medicaid Services in Denver. Dr. Levine founded the Colorado Patient Safety Coalition and served as chair of the American Medical Association’s Council on Ethical & Judicial Affairs. He received his bachelor’s degree from Rutgers University and medical degree from Temple University School of Medicine.
Dr. Levine’s father, Dr. Phillip Levine, was a pioneering hematologist who joined Ortho Products in 1944 and his breakthrough discovery of Rh factor led to advancements in hemolytic disease of the newborn and safe blood transfusions saving countless lives.
-
Transfusion reactions are adverse events associated with the transfusion of whole blood or one of its components. They range in severity from minor to life-threatening and can occur during a transfusion, termed acute transfusion reactions, or days to weeks later, termed delayed transfusion reactions. Transfusion reactions may be difficult to diagnose as they can present with non-specific, often overlapping symptoms. The most common signs and symptoms include fever, chills, urticaria, and itching. Some symptoms may resolve with little or no treatment. However, respiratory distress, high fever, hypotension, and hemoglobinuria may indicate a more serious reaction. All cases of suspected reactions should prompt immediate discontinuation of the transfusion and notification of the blood bank and treating clinician. Learn in this podcast episode the evaluation and management of transfusion reactions and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.
About our Speaker:
Dr. Aaron Tobian received his medical degrees from Case Western Reserve University. He is highly involved with the transfusion medicine community serving on the Association for the Advancement of Blood and Biotherapies' Board of Directors and is president-elect of the board. Dr. Tobian has authored more than 300 peer-reviewed articles in journals, including The New England Journal of Medicine, JAMA, Blood, and TRANSFUSION, and has been featured on BBC World Service, Today Show, National Public Radio, and USA Today. He is board certified in clinical pathology and blood banking/transfusion medicine and divides his time between research and clinical service.
-
Alloimmune hemolytic disease of the fetus and newborn (HDFN) may occur when a pregnant woman has an antibody against an antigen on the fetal red cells inherited from the father. Many antibodies to red blood cell antigens can cause HDFN, including those from the ABO, Rh, and other blood group systems. Women can develop antibodies either through previous pregnancy or transfusion. Fatal consequences from this disorder have become rare with the appropriate use of immunoprophylaxis. However, to avoid the fatal consequences of this disorder, prompt recognition and treatment are vital. The risk for HDFN can be identified by testing the mother with an ABO group/Rh and antibody screen during the pregnancy. RhD HDFN can be prevented through passive anti-D administration to suppress the mother’s immune response against the fetal RhD antigen. Some women may exhibit weak or discrepant results on RhD typing, or current results may differ from historical results. A common type of RhD variant is the weak D phenotype. Women with this phenotype have a weak expression of the RhD antigen and may present with variable RhD typing depending on the antisera or testing method used in the laboratory. Another type of RhD variant is the partial D phenotype where the RhD antigen is altered, potentially allowing an individual to form alloantibodies to the epitopes on RhD-positive red blood cells that are different than their own. In this podcast episode, we will discuss the types of HDFN, the role that partial D groups, and the presence of anti-D as it relates to its prevalence, prognosis, and management.
About our Speaker:
Dr. Genghis Lopez is a Senior Scientist at the Australian Red Cross Lifeblood in Brisbane, Australia. Genghis received his Ph.D. degree from Griffith University, Australia. At Lifeblood, he worked at the Platelet and Granulocyte Reference Laboratory and Red Cell Reference Laboratory and is now part of the Transfusion Science research team that investigates complex red cell blood group variants. He has published several papers in Vox Sanguinis and Transfusion journals reporting novel red cell antigens, novel blood types, and red cell antibodies including several associated with hemolytic transfusion reactions or hemolytic disease of the fetus and the newborn.
-
According to the American Thyroid Association, as many as 60 percent of those with a thyroid disorder are unaware of their condition, and women are 5 to 8 times more likely than men to develop thyroid disease. If left untreated, thyroid dysfunction increases an individual’s risk for other serious conditions such as cardiovascular disease, infertility and osteoporosis.
Laboratory testing plays an important role to help diagnose and monitor thyroid disease states.
About our Speaker:
Dr. Rea Castro is the Director of Medical Affairs at QuidelOrtho. She holds a Bachelor’s degree in Medical Technology from the University of Santo Tomas and a Medical Degree from the University of the East in the Philippines, and a Master’s in Public Health from Northern Illinois University in the United States. She has experience in both clinical and biotechnology product development covering multiple therapeutic areas. As the head of Medical Affairs, she is responsible for providing medical support of QuidelOrtho’s products throughout the assay lifecycle. Her clinical focus before going into the industry was in Women’s Health.
-
The fascinating history of the discovery of blood groups goes back to 1900 with the breakthrough that came when Dr. Karl Landsteiner, an Austrian scientist, discovered three human blood groups. These were the A, B, and O blood groups. Two students who worked with Karl Landsteiner discovered the fourth human blood group, the AB. These two were A. van Decastello and A. Sturli. These four blood groups together are what we today know as the ABO blood group system.
In this podcast episode with Dr. Jill Storry, you will learn the fascinating journey behind discovering blood groups and stay up to date on the latest blood groups that have been discovered.
About our Speaker:
Jill Storry, PhD, Lund University, Sweden
Dr. Jill Storry is a professor at the Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, and is responsible for the immunohematology laboratories in the Department of Clinical Immunology and Transfusion Medicine. She is an American Association of Blood Banking (AABB) National Blood Foundation Scholar for her discovery of the genetic basis of the Vel blood group system. Her awards include the British Blood Transfusion Society’s Margaret Kenwright and Race & Sanger awards, the AABB’s Sally Frank Award, and an ISBT award for outstanding contributions to education. Dr. Storry has authored more than 60 original papers, reviews, and textbooks, and spoken at more than 100 international and national conferences and courses. She is a member of the editorial board of Transfusion Medicine Reviews, Transfusion and Immunohematology, and section editor for Vox Sanguinis.
-
The cybersecurity landscape continues to evolve. Health Care Companies Are the #1 Target for Cyberattacks and Data Breaches. The pace of the release of cybersecurity guidance and regulations for medical devices across the globe has been accelerating. Globally, some regulatory bodies have restricted their guidance to premarket concerns, and others have provided guidelines to include post-market considerations. One of the key tenants of all post-market cybersecurity guidance and regulations is the manufacturer’s responsibility to evaluate and maintain their product cybersecurity continually. This additional level of scrutiny and regulations only increases the need to act now. To prepare for and combat these cyberattacks, healthcare companies must make the necessary investments in people, processes, and technology. A reactive approach to cybersecurity is no longer feasible. It’s time to anticipate and prevent these attacks before they even arrive. Learn in this episode how new, predictive technologies analyze past threats to identify future threats. Ideally, this results in the detection of potentially harmful files or behaviors before an attack is successful.
About Our Speaker:As Ortho Clinical Diagnostic’s Chief Information Security Officer, Patty Ryan is responsible for defining the firm’s global Information Security strategy, roadmap, and operating infrastructure. Partnering globally with IT, Compliance, Commercial, Regulatory, Legal, Quality, R&D, and Strategic Marketing resources, she ensures that all Information Security controls operate effectively and efficiently, that staff is aware of their responsibility to protect client and proprietary information, and that the security team defines and manages information risk appropriately. Patty has over 30 years of IT experience, over half of that in Information Security executive positions. She has worked in financial services (Bankers Trust, Citi, CitiStreet), life sciences (Johnson & Johnson), and legal (Fragomen, Del Rey, Bernsen, and Loewy LLP) and brings a wide range of experience to Ortho. She holds a BA in Economics from Columbia College, Columbia University, and an Executive MBA from the Stern School of Business at New York University.
-
World Diabetes Day takes place each year in the month of November, created to raise awareness about the disease. Diabetes is a global health threat diabetes with the number of people living with diabetes continuing to rise. Diagnostic testing is one of the major tools to help prevent and manage the disease.
About our Speaker:
Dr. Amy L. Pyle earned her Ph.D. in Molecular Pathology from Vanderbilt University. Following graduate school, Dr. Pyle completed a post-doctoral fellowship in Clinical Chemistry at Vanderbilt University. Dr. Pyle took a position as Assistant Director of Core Laboratories at Nationwide Children's Hospital in 2011. Throughout her training, Dr. Pyle published multiple abstracts, papers, and book chapters, and has received numerous awards for her contributions to the scientific community.
-
High-prevalence antigens occur in greater than 99% of the population. Antibodies to high-prevalence antigens are rare and may be difficult to identify due to the lack of antigen-negative panel cells for these antigens. Examples of antibodies to high-prevalence antigens are: anti-k, anti-Kpb, anti-Jsb, and anti-Lub among many othersThere is a need to proper identify these antibodies before transfusion to differentiate clinically significant antibodies, that could cause hemolytic transfusion reactions or hemolytic disease of the fetus and newborn from those with little or no clinical relevance. Their specific identification is often difficult, labor-intensive, and time-consuming and it may be difficult to find antigen-negative compatible blood for the patient in need of a transfusion
Learn in this episode clues to recognize if an antibody to a high-prevalence antigen is present and how to apply practices for their identification in the lab and additional recommendations for patient management.
About Our Speaker:
Shane Grimsley, DipRCPath; holds a diplomate in Pathology from the Royal College of Pathologists, UK and has been working at the International Blood Group Reference Laboratory, NHSBT in the UK since 2009, as laboratory manager from 2015 and Senior Clinical Scientist since 2020. Since 2017, Shane has been the lead scientific advisor to the UK NEQAS Red Cell Genotyping scientific advisory group, compiling complex reports to help educate the users. He has been an active member of the editorial board for Immunohematology as well as a reviewer for Vox Sanguinis and Transfusion Medicine since 2019.
Shane is the winner of the 2020 Race and Sanger award from the British Blood Transfusion Society for outstanding contribution to the field of Transfusion, primarily for his work developing a genotyping platform for accurate prediction of variant phenotypes in patients with Sickle Cell Disorder. He also is a winner of the 2010 Margaret Kenwright Young Scientist of the year from the British Blood Transfusion Society, for his work resolving complex compound heterozygous allele combinations and the identifying the associated antibody specificities.
Shane is an international scientific speaker and a workshop instructor for immunohematology topics in conference programs, such as ISBT. He also has been involved in the identification of new blood group systems, new antigens and novel alleles. Shane is helping lead a team of skilled and passionate scientists to resolve the world’s most complex immunohematology cases, contributing to ground-breaking projects that have improved the standards of care for patients.
-
Sepsis occurs when the body’s immune system responds to an infection and injures its own tissues and organs. It is a medical emergency, requiring early detection and treatment as it can lead to septic shock, multi-organ failure, and death. One in five deaths worldwide is associated with sepsis and 40% of cases are in children under five years of age. Sepsis is the number one cause of death in hospitals, the number one cause of hospital readmissions, and the number one healthcare cost.
Laboratory testing is essential in helping prevent, detect, and treat sepsis to minimize injury to the body and the risk of death.
About Our Speaker:
Dr. Lui Forni is a Professor and Consultant Nephrologist and Intensivist at Royal Surrey County Hospital NHS Foundation Trust in Guildford, England. Professor Forni earned a PhD in physical chemistry and subsequently studied medicine, specializing in nephrology and intensive care medicine. His research interests include pre-operative assessment of high-risk surgical candidates, renal replacement therapy, diagnosis, pathophysiology and treatment of acute kidney injury, and predictive modeling in acute medical admissions. He lectures both nationally and internationally and has published widely. He served as the Past Research Chair and is the Current Secretary of the European Society of Intensive Care Medicine.
-
A rare donor program is a collaborative effort of many blood centers and/or hospitals to combine their rare donor resources to supply what they have to patients in need. These centers work to identify rare donors by screening methods and inclusion in database systems.
Learn in this episode what resources are available to the medical community to ensure availability for patients in need of blood and why it is critical to national and international collaboration through joint programs.
About our Speaker:
Sandra Nance has provided leadership to the American Rare Donor Program, American Red Cross Histocompatibility and Immunogenetics laboratories, the National Reference Laboratories for Blood Group Serology, Molecular Testing, Neutrophil and Specialized Testing. She engineered the nationalized American Red Cross SBB Program. She is now a volunteer for the American Red Cross and Emeritus Adjunct Assistant Professor at the University of Pennsylvania in the Department of Pathology and Laboratory Medicine. She earned her Master in Pathology from the University of Maryland and her SBB from The Johns Hopkins Medical Institutions. Ms. Nance held leadership positions in the AABB, ASCP, ICII, and ISBT. She chaired the ISBT Working Party on Rare Donors and conceptualized the ISBT Working Party on Immunohematology, and as the past Chair, managed the Case Studies.She has been inducted into the ASCP and the National Blood Foundation Halls of Fame and has received the AABB’s Sally Frank, John Elliott and President’s Awards, AIMS John Moulds, CBBS Suzanne Ledin, MAABB Kay Beattie, New York Supervisors Ron Dubin, and UTMB Jean Stubbins awards. She is the past Editor in Chief of Immunohematology Journal of Blood Group Serology and Molecular Genetics, is a member of Transfusion’s Editorial Board and reviews for several journals. She developed the polyethylene glycol method for serologic testing and the monocyte monolayer assay (MMA) to predict in vivo survival of transfused incompatible red cells. She initiated the International MMA Training classes so other countries can implement the MMA to assist with patients requiring rare blood. Ms. Nance has been invited to present over 250 lectures and has been a frequent contributor to the scientific literature.
-
In Sickle Cell Disease (SCD) patients, one of the most critical treatments is a blood transfusion. A blood transfusion is used to provide normal red blood cells to the patient’s body. Red blood cell transfusions help lessen anemia and reduce the blood’s viscosity, allowing it to flow more freely, ease disease symptoms and prevent complications. Alloimmunization is common in patients with SCD and may complicate transfusion therapy. For many patients, a close blood type match is essential and is found in donors of the same race or similar ethnicity.
In this episode, learn why patient phenotyping and prophylactic matching to reduce alloimmunization is recommended for SCD patients and why donor source for blood donations of the same race or similar ethnicity is critical.
About the Speaker:
Dr. Stella T. Chou is Chief of the Division of Transfusion Medicine, board-certified in Blood Banking and Transfusion Medicine, and an attending physician in the Division of Hematology at Children's Hospital of Philadelphia. Dr. Chou earned her medical degree from New York Medical College in Valhalla, NY. She specializes in caring for children with SCD, those who make antibodies against red blood cell transfusions (alloimmunization), and those requiring apheresis. Her research interests are focused on improving red blood cell matching for patients through the use of innovative tools.
Her work has demonstrated that inheritance of variant blood group antigens in patients with SCD contributes to their high rate of red blood cell antibody formation. Her ongoing work focuses on the genetic matching of red blood cells and creating customized induced pluripotent stem cells (iPSCs) with rare blood group antigen combinations as renewable sources of red blood cell reagents to improve antibody identification and donor red blood cell matching. For her innovative research, she is a recipient of the National Blood Foundation Hall of Fame award. Dr. Chou is a worldwide recognized author and speaker with over 100 publications and lectures. In addition to her clinical work, Dr. Chou serves as an Associate Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania.
-
Review the role of extended antigen typing or phenotyping in Transfusion Medicine. How this practice plays a significant role in the transfusion of sickle cell, thalassemia, and myelodysplastic syndrome patients as well as other chronically transfused patients, preventing the development of foreign antibodies which may avoid the challenges that come later with complex antibody problems and brings the additional benefit of allowing finding compatible blood for patients in need of a transfusion. In this podcast edition, we will explore those key points and more.
About our Speaker: Tony S. Casina, MT(ASCP)SBB has worked in the blood banking industry for over 40 years with much of it in the commercial blood bank reagent manufacturers sector with hospital experience as a medical technologist and blood bank manager. Tony has provided technical support to laboratories throughout the world utilizing Ortho’s reagents and immunohematology test systems. He has tested some of the most challenging antibody problems as part of his reference laboratory experience. Tony has been an active participant in the AABB serving on committees and currently on the AABB Board of Directors. He has contributed as a presenter to AABB and regional blood bank meetings educational programs. He was extensively involved in the development of the ORTHO VISION® Analyzer Platform.
-
The World Health Organization estimated that during 2019, 58 million people worldwide were living with the Hepatitis C virus (HCV) which causes inflammation of the liver. All types of hepatitis can be controlled or prevented. There is a cure for Hepatitis C; however, HCV infection is often undiagnosed because it remains asymptomatic until symptoms appear that are related to serious liver damage, a complication of the infection.
ABOUT THE SPEAKER
Dr. Bijal Parikh is the Medical Director of the Molecular Diagnostics Laboratory and Assistant Professor of Pathology & Immunology at Washington University in St. Louis, Missouri.
He is the author of numerous publications with his clinical research centered on aspects of laboratory testing involving viral, immunologic, and molecular diagnostics, with a specific focus on the implementation of next-generation sequencing approaches. Recently, Dr. Parikh authored an article published in the Clinical Microbiology Newsletter titled Laboratory Strategies for Diagnosis and Monitoring of Hepatitis C Virus Infection.
-
Maternal health refers to the health of the women during pregnancy, childbirth, and the postnatal period. Each stage should be a positive experience, ensuring women and their babies reach their full potential for health and well-being. Prenatal care includes screening and diagnostic tests and they can provide valuable information about the baby's health. Understand the risks and benefits.The obstetrician in partnership with the laboratory has tools that can contribute to maternal health, such as:• Prenatal screening tests which can identify potential genetic disorders and diagnostic tests, and,• Diagnostic test, which is the only way to be sure of a diagnosis.
Learn in this episode what are the strategies to minimize the risk of alloimmunization in the maternal population and what are the recommendations for antenatal and post-delivery care testing.
About Our Speaker:
Professor Robert Flower is a national leader in R&D at the Australian Red Cross Lifeblood. He has been teaching and supervising hospital and university blood banks for over 30 years. He has published over 400 publications with over 4000 citations and has helped over 50 students complete post-graduate research. In 2018, Dr. Flower was granted the Vice Chancellor’s Award for Excellence at Queensland University of Technology. The following year, he was awarded the Peter Schiff Award from the Australia and New Zealand Society for Blood Transfusion. Dr. Flower’s current interests include translating genetics to routine investigations, molecular modeling of the structures defining blood groups, and evidence-based modeling of the risk of transfusion-transmission for various agents.
- Visa fler
